Evidence Table 2Quality Assessment of Randomized Controlled Trials

Randomization adequate?Allocation concealment adequate?Groups similar at baseline?Eligibility criteria specified?Outcome assessors masked?Care provider masked?Patient masked?Intention-to-treat analysisMaintenance of comparable groupsAcceptable levels of crossovers, adherence, and contamination?Acceptable levels of overall attrition and between-group differences in attrition?Quality rating
Altman 2009UnclearUnclearYesYesYesYesYesYesYesUnclear, Unclear, UnclearYes, YesFair
Baer 2005YesYesYesYesYesYesYesYes, only excluded 4/216 (2%)YesUnclear, Yes, UnclearOverall=No (28%) Between-group=YesFair
Barkhuizen 2006UnclearUnclearYesYesUnclearUnclearUnclearUnclear; analyses performed on patients who took ≥ dose of studyUnclearUnclear, Unclear, UnclearNo; 33% overall Yes; celecoxib 200 mg=27%, celecoxib 400Fair
Barthel 2009UnclearUnclearYesYesYesYesYesYes, only excluded 1/492 (0.2%)YesUnclear, Yes, UnclearYes, YesFair
Bookman 2004YesUnclearYesYesYesYesYesYes; only excluded 1/248 (0.4%)YesUnclear, Yes, UnclearYes, YesFair
Chan 2007YesYesYesYesYesYesYesYesYesUnclear, Yes, YesYes, YesGood
Chan 2010 (CONDOR)YesYesYesYesYesYesYesYesYesUnclear, Unclear, UnclearYes, YesGood
Dahlberg 2009YesYesYesYesUnclearYesYesYes, for primary outcome and AEs; No, for other comparisonsYesUnclear, Unclear, UnclearYes-although attrition high, subjects were elderly and duration of study was 1 year; Yes-similar attrition in both groupsFair
Dentali 2006YesYesUnclear; baseline characteristics not compared based on order of randomizationYesYesYesYesYesyesUnclear, Yes, UnclearNo, Unclear Overall=4/26 (27%) Between-group=Group assignment not reported for 2 withdrawalsFair
Emery, 2007YesUnclearNo. Statistics not given for randomizedYesUnclearYesYesNo. 5.6%) of subjects not analyzed in "modifiedDo not know that they were similar atUnclear, unclear, unclearNo-40% loss in 12 week study. Yes, similarPoor
Goldstein, 2007YesUnclearYesYesUnclearYesYesYesYesUnclear, adherence, unclearYes, YesFair
Herrera, 2007YesUnclearYesYesUnclearYesYesYesYesUnclear, unclear, unclearYes, YesFair
Niethard 2005YesYesYes, for the most part, Diclofenac patients haveYesYesYesYesYesYesUnclear, Unclear, UnclearYes, YesGood
Prabhu 2008UnclearUnclearUnclearYesUnclearNoNoYesYesUnclear, Unclear, UnclearUnclear, UnclearFair
Roth 1995UnclearUnclearYesYesUnclearUnclearUnclearUnclearUnclearUnclear, Unclear, UnclearYes, YesPoor
Roth 2004YesYesYesYesYesYesYesYes, only excluded 4/326 (1.2%)YesUnclear, Yes, UnclearOverall=No, 30% Differential=YesFair
Sieper 2008UnclearUnclearUnclear, not shownYesUnclearYes; double-dummyYes; double-dummyYes; only excluded 4/458 (0.9%) from "full analysis set"YesUnclear, Unclear, UnclearYes; 77/458(16.8%) overall YesFair
Simon 2009YesYesYesYesUnclearYes; double dummyYes; double dummyYes; only excluded 0.4%YesUnclear, Yes-89%, UnclearOverall=No, 32% Differential=YesFair
Tugwell 2004YesYesYesYesUnclearYesYesYes; only excluded 18/622(3%)YesUnclear, Yes, UnclearOverall=No, 39% Differential=YesFair
Wagenitz, 2007YesUnclearYesYesUnclearYesYesYesYesUnclear, unclear, unclearYes, YesFair

From: Evidence Tables

Cover of Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet].
Peterson K, McDonagh M, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2010 Nov.
Copyright © 2010, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.